Effect of vaccine Vacc-4x, romidepsin and neutralizing antibody (bNAB), in HIV-1 infections

Trial Profile

Effect of vaccine Vacc-4x, romidepsin and neutralizing antibody (bNAB), in HIV-1 infections

Planning
Phase of Trial: Phase I/II

Latest Information Update: 27 Jan 2017

At a glance

  • Drugs Vacc-4x (Primary) ; Antibodies; Romidepsin
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms BIONAB
  • Most Recent Events

    • 27 Jan 2017 According to a Bionor media release, the Research Council of Norway (RCN) through its BIA Program (Brukerstyrt Innovasjonsarena), has awarded the company up to NOK 10.3 million to partially fund this exploratory trial.
    • 02 Oct 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top